Olopade OI - Search Results

1

Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.

Young NR, Soneru C, Liu J, Grushko TA, Hardeman A, Olopade OI, Baum A, Solca F, Cohen EE. Young NR, et al. Among authors: olopade oi. Target Oncol. 2015 Dec;10(4):501-8. doi: 10.1007/s11523-014-0353-6. Epub 2015 Jan 6. Target Oncol. 2015. PMID: 25559287 Free PMC article.

2

Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.

Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, Olopade OI. Grushko TA, et al. Among authors: olopade oi. Cancer Res. 2002 Mar 1;62(5):1481-8. Cancer Res. 2002. PMID: 11888924

3

MYC is amplified in BRCA1-associated breast cancers.

Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, Ridderstråle KK, Anderson KN, Wei MJ, Adams AJ, Hagos FG, Sveen L, Lynch HT, Weber BL, Olopade OI. Grushko TA, et al. Among authors: olopade oi. Clin Cancer Res. 2004 Jan 15;10(2):499-507. doi: 10.1158/1078-0432.ccr-0976-03. Clin Cancer Res. 2004. PMID: 14760071

4

Single-day FISH procedure for paraffin-embedded tissue sections using a microwave oven.

Ridderstråle KK, Grushko TA, Kim HJ, Olopade OI. Ridderstråle KK, et al. Among authors: olopade oi. Biotechniques. 2005 Sep;39(3):316, 318, 320. doi: 10.2144/05393BM04. Biotechniques. 2005. PMID: 16206903 Free article. No abstract available.

5

BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.

Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI. Wei M, et al. Among authors: olopade oi. Cancer Res. 2005 Dec 1;65(23):10692-9. doi: 10.1158/0008-5472.CAN-05-1277. Cancer Res. 2005. PMID: 16322213

6

Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.

Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, Grushko TA, Olopade OI. Wei M, et al. Among authors: olopade oi. Breast Cancer Res Treat. 2008 Sep;111(1):113-20. doi: 10.1007/s10549-007-9766-6. Epub 2007 Oct 12. Breast Cancer Res Treat. 2008. PMID: 17932744 Free PMC article.

7

Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.

Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE. Choong NW, et al. Among authors: olopade oi. J Thorac Oncol. 2008 Sep;3(9):1003-11. doi: 10.1097/JTO.0b013e31818396a4. J Thorac Oncol. 2008. PMID: 18758303 Free PMC article. Clinical Trial.

8

Advances in breast cancer: pathways to personalized medicine.

Olopade OI, Grushko TA, Nanda R, Huo D. Olopade OI, et al. Clin Cancer Res. 2008 Dec 15;14(24):7988-99. doi: 10.1158/1078-0432.CCR-08-1211. Clin Cancer Res. 2008. PMID: 19088015 Free PMC article. Review.

9

Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.

Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI. Huo D, et al. Among authors: olopade oi. J Clin Oncol. 2009 Sep 20;27(27):4515-21. doi: 10.1200/JCO.2008.19.6873. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704069 Free PMC article.

10

Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?

Burness ML, Grushko TA, Olopade OI. Burness ML, et al. Among authors: olopade oi. Cancer J. 2010 Jan-Feb;16(1):23-32. doi: 10.1097/PPO.0b013e3181d24fc1. Cancer J. 2010. PMID: 20164687 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

507 results

Search Page